Salubris Reports 8.95% YoY Decline in 2023 Net Profit; Yifan Pharma's Long-Acting G-CSF Ryzneuta Approved in EU
Salubris
Pharmaceutical Product R&D Developer
cellgenes
Stem Cell New Drug Developer
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer
Staidson
Innovative Drug Research and Development Manufacturer
Phanes China
Antibody New Drug Developer
Pharmaceutical companies' financial reports are being released one after another.
On March 25, Salubris announced that it achieved revenue of 3.365 billion yuan in 2023, a year-on-year decrease of 3.35%; net profit was 580 million yuan, a year-on-year decrease of 8.95%.
Cryotherapeutics also announced that it achieved operating revenue of 473 million yuan in 2023, representing a year-on-year increase of 19.8%; the adjusted net profit was 42.43 million yuan, marking a year-on-year growth of 22.1%. What’s your take on the performance of these companies?
China-produced innovative drugs achieve another success in overseas expansion.
On March 24, Yifan Pharmaceutical announced that Ryzneuta, a long-acting granulocyte colony-stimulating factor (G-CSF), had been approved by the European Commission for marketing in the EU.
On March 25, Phanes announced that the U.S. FDA granted Fast Track designation to its Claudin 18.2/CD47 bispecific antibody PT886 for the treatment of patients with metastatic Claudin 18.2-positive pancreatic cancer.
What are the hot topics worth paying attention to in the pharmaceutical market in China and abroad in the past day? Let Amino take you through them.
/ 01 /
Capital Information
1) Salubris' net profit in 2023 decreased by 8.95% year-on-year
On March 25, Salubris announced that it achieved revenue of 3.365 billion yuan in 2023, a year-on-year decrease of 3.35%; net profit was 580 million yuan, a year-on-year decrease of 8.95%.
2) CiTech's 2023 revenue increased by 19.8% year-over-year
On March 25, Cercacor announced that it achieved revenue of 473 million yuan in 2023, representing a year-on-year increase of 19.8%; the adjusted net profit was 42.43 million yuan, marking a year-on-year growth of 22.1%.
/ 02 /
Pharmaceuticals and Medical Devices Updates
1) Cellgenes' CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection Approved for Clinical Trials
On March 25, according to the CDE official website, cellgenes' CG-BM1 allogeneic human bone marrow mesenchymal stem cell injection has been approved for clinical trials, aiming to conduct research on the treatment of ischemic stroke.
2) Hengrui Pharma's Fluazoparib Capsules Granted Breakthrough Therapy Designation
On March 25, according to the CDE website, Hengrui Pharma's fluzoparib capsule is proposed to receive breakthrough therapy designation for the treatment of HER2-negative breast cancer with gBRCA mutations, either as monotherapy or in combination with apatinib.
3) Staidson Terminates COVID-19 Therapy Development
On March 25, Staidson issued an announcement stating that, based on the current situation of the COVID-19 pandemic, it has decided to terminate the research work on the COVID-19 indication direction for BDB-001 Injection, STSA-1002 Injection, STSA-1005 Injection, and the combination therapy of STSA-1002 and STSA-1005.
4) Phanes' Claudin 18.2/CD47 Bispecific Antibody Granted FDA Fast Track Designation
On March 25, Phanes announced that the U.S. FDA granted Fast Track designation to its Claudin 18.2/CD47 bispecific antibody PT886 for the treatment of patients with metastatic Claudin 18.2-positive pancreatic cancer.
5) Yifan Pharmaceutical's Long-Acting Granulocyte Colony-Stimulating Factor Approved by the EU
On March 24, Yifan Pharmaceutical Co., Ltd. announced that Ryzneuta, a long-acting granulocyte colony-stimulating factor (G-CSF), has been approved by the European Commission for marketing in the EU.
6) Z众生药业: Top-line Analysis Data Results Obtained for Phase I Clinical Trial of Innovative Drug RAY1225 Injection
On March 25, Z众生药业 (Zhenzhong Pharmaceutical) announced that its holding subsidiary's Class I innovative drug RAY1225 injection obtained the topline analysis data results from the Phase I clinical trial. The RAY1225 injection significantly reduced the weight of overweight or obese subjects, with ideal trial results achieving the expected objectives.
/ 03 /
Overseas Pharma News
1) AstraZeneca's Long-Acting C5 Complement Inhibitor Receives FDA Approval for Neuromyelitis Optica Treatment
On March 25, AstraZeneca announced that the FDA had approved the new indication for the long-acting C5 complement inhibitor Ultomiris, for the treatment of aquaporin-4 antibody-positive neuromyelitis optica.
2) Novo Nordisk Acquires Cardior for €1.025 Billion
On March 25, Novo Nordisk announced the acquisition of Cardior for €1.025 billion. Cardior is a biotech company focused on discovering and developing RNA-targeted therapies to prevent, repair, and reverse heart disease.
3) AbbVie's FRα ADC Receives Full FDA Approval
Recently, AbbVie announced that the U.S. FDA has fully approved its FRα ADC drug Elahere, indicated for the treatment of patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have previously received up to three systemic treatment regimens.
4) EU Delays Approval of Lecanemab for Alzheimer's
Recently, Eisai announced that due to procedural reasons, the Committee for Medicinal Products for Human Use of the European Medicines Agency will reschedule the review of the marketing authorization application for the new Alzheimer's drug lecanemab, leading to a delay in the EMA’s decision on the approval of lecanemab.
5) Pfizer CEO: AI Will Change the Future of the Pharmaceutical Industry
On March 25, Albert Bourla, Chairman and CEO of Pfizer, discussed how biotechnology is continuously evolving, with advancements in other technologies keeping pace. AI is disruptive for everyone and will completely transform the future of the pharmaceutical industry.
Text / Huang Kai
PS: Welcome to scan the QR code below to add Amino's WeChat for communication.
